In wake of Bio­gen's skir­mish with the SEC, phar­ma gi­ants are chang­ing the way they do quar­ter­ly re­ports

Af­ter re­ceiv­ing com­plaints from the SEC last spring, Bio­gen changed the way it re­ports up­front pay­ments to col­lab­o­ra­tors in its quar­ter­ly up­dates. But it ap­pears …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER